{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:39:10Z","timestamp":1785213550328,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,6,11]],"date-time":"2010-06-11T00:00:00Z","timestamp":1276214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00223-010-9383-y","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T08:01:31Z","timestamp":1276156891000},"page":"120-129","source":"Crossref","is-referenced-by-count":50,"title":["Bone Mineral Density and Fracture Rate in Response to Intravenous and Oral Bisphosphonates in Adult Osteogenesis Imperfecta"],"prefix":"10.1007","volume":"87","author":[{"given":"Jay R.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol B.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolynn","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,11]]},"reference":[{"key":"9383_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11914-007-0023-z","volume":"5","author":"E Martin","year":"2007","unstructured":"Martin E, Shapiro JR (2007) Osteogenesis imperfecta: epidemiology and pathophysiology. Curr Osteoporos Rep 5:91\u201397","journal-title":"Curr Osteoporos Rep"},{"key":"9383_CR2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajmg.c.30072","volume":"15","author":"F Rauch","year":"2005","unstructured":"Rauch F, Glorieux FH (2005) Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet C Semin Med Genet 15:31\u201337","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"9383_CR3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/humu.20799","volume":"29","author":"D Baldridge","year":"2008","unstructured":"Baldridge D, Schwarze U, Morello R, Lennington J, Bertin TK, Pace JM, Pepin MG, Weis M, Eyre DR, Walsh J, Lambert D, Green A, Robinson H, Michelson M, Houge G, Lindman C, Martin J, Ward J, Lemyre E, Mitchell JJ, Krakow D, Rimoin DL, Cohn DH, Byers PH, Lee B (2008) CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat 29:1435\u20131442","journal-title":"Hum Mutat"},{"key":"9383_CR4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","volume":"85","author":"FS Dijk van","year":"2009","unstructured":"van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR, Fratantoni SA, Jimenez CR, Huizer M, Morsman AC, Cobben JM, van Roij MH, Elting MW, Verbeke JI, Wijnaendts LC, Shaw NJ, H\u00f6gler W, McKeown C, Sistermans EA, Dalton A, Meijers-Heijboer H, Pals G (2009) PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet 85:521\u2013527","journal-title":"Am J Hum Genet"},{"key":"9383_CR5","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2006-2023I","volume":"119","author":"FH Glorieux","year":"2007","unstructured":"Glorieux FH (2007) Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics 119:S163\u2013S165","journal-title":"Pediatrics"},{"key":"9383_CR6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/adc.2006.096552","volume":"92","author":"E Astr\u00f6m","year":"2007","unstructured":"Astr\u00f6m E, Jorulf H, S\u00f6derh\u00e4ll S (2007) Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 92:332\u2013338","journal-title":"Arch Dis Child"},{"key":"9383_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","volume":"51","author":"H Castillo","year":"2009","unstructured":"Castillo H, Samson-Fang L (2009) Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Dev Med Child Neurol 51:17\u201329","journal-title":"Dev Med Child Neurol"},{"key":"9383_CR8","doi-asserted-by":"crossref","unstructured":"Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 4:CD005088","DOI":"10.1002\/14651858.CD005088.pub2"},{"key":"9383_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101\u2013116","journal-title":"J Med Genet"},{"key":"9383_CR10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","volume":"9","author":"SF Hodgson","year":"2003","unstructured":"Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR AACE, Force Osteoporosis Task (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544\u2013564","journal-title":"Endocr Pract"},{"key":"9383_CR11","volume-title":"Analysis of longitudinal data","author":"PJ Diggie","year":"2002","unstructured":"Diggie PJ, Heagerty P, Liang KY, Zieger SL (2002) Analysis of longitudinal data. Ozford University Press, New York"},{"key":"9383_CR12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1754-4505.2008.00070.x","volume":"29","author":"R Saeves","year":"2009","unstructured":"Saeves R, Lande Wekre L, Ambj\u00f8rnsen E, Axelsson S, Nordgarden H, Storhaug K (2009) Oral findings in adults with osteogenesis imperfecta. Spec Care Dentist 29:102\u2013108","journal-title":"Spec Care Dentist"},{"key":"9383_CR13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3766\/jaaa.19.8.3","volume":"19","author":"JP Pillion","year":"2008","unstructured":"Pillion JP, Shapiro JR (2008) Audiological findings in osteogenesis imperfecta. J Am Acad Audiol 19:595\u2013601","journal-title":"J Am Acad Audiol"},{"key":"9383_CR14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","volume":"21","author":"LA DiMeglio","year":"2006","unstructured":"DiMeglio LA, Peacock M (2006) Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21:132\u2013140","journal-title":"J Bone Miner Res"},{"key":"9383_CR15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G (2002) Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508\u2013516","journal-title":"Endocr Rev"},{"key":"9383_CR16","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR FLEX, Group Research (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"9383_CR17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","volume":"21","author":"G Chevrel","year":"2006","unstructured":"Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21:300\u2013306","journal-title":"J Bone Miner Res"},{"key":"9383_CR18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tat\u00f2 L (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126\u2013130","journal-title":"J Bone Miner Res"},{"key":"9383_CR19","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","volume":"310","author":"CR Paterson","year":"1984","unstructured":"Paterson CR, McAllion S, Stellman JL (1984) Osteogenesis imperfecta after the menopause. N Engl J Med 310:1694\u20131696","journal-title":"N Engl J Med"},{"key":"9383_CR20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jbmr.5650100718","volume":"10","author":"NS Fedarko","year":"1995","unstructured":"Fedarko NS, Robey PG, Vetter U (1995) Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J Bone Miner Res 10:1122\u20131129","journal-title":"J Bone Miner Res"},{"key":"9383_CR21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00003086-199703000-00034","volume":"336","author":"EF McCarthy","year":"1997","unstructured":"McCarthy EF, Earnst K, Rossiter K, Shapiro J (1997) Bone histomorphometry in adults with type 1A osteogensis imperfecta. Clin Orthop Relat Res 336:254\u2013262","journal-title":"Clin Orthop Relat Res"},{"key":"9383_CR22","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bone.2004.02.023","volume":"34","author":"V Braga","year":"2004","unstructured":"Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O (2004) Bone turnover markers in patients with osteogenesis imperfecta. Bone 34:1013\u20131016","journal-title":"Bone"},{"key":"9383_CR23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bone.2008.11.006","volume":"44","author":"P Garnero","year":"2009","unstructured":"Garnero P, Schott AM, Prockop D, Chevrel G (2009) Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations. Bone 44:461\u2013466","journal-title":"Bone"},{"key":"9383_CR24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s00198-009-0991-1","volume":"21","author":"MM Wilkes","year":"2010","unstructured":"Wilkes MM, Navikis RJ, Chan WW, Lewiecki EM (2010) Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant\/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int 21:676\u2013688","journal-title":"Osteoporos Int"},{"key":"9383_CR25","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","volume":"25","author":"MG Seikaly","year":"2005","unstructured":"Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25:786\u2013791","journal-title":"J Pediatr Orthop"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-010-9383-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-010-9383-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-010-9383-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T07:37:58Z","timestamp":1558683478000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-010-9383-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,11]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["9383"],"URL":"https:\/\/doi.org\/10.1007\/s00223-010-9383-y","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,11]]}}}